PROLOR Biotech, Inc.

Type: Public
On the web: http://www.prolor-biotech.com
Employees: 27
Employee growth: 58.8%

One day PROLOR Biotech hopes to have a human growth hormone product that can be injected twice a month instead of daily and an interferon beta for multiple sclerosis that has lower side effects. The biopharmaceutical company is in the early stages of developing therapeutic proteins that are enhanced with Carboxyl Terminal Peptide (CTP), an amino acid that can help render drugs longer lasting. The company licenses certain rights to the peptide from Washington University with the goal of commercializing improved versions of already-approved therapeutic proteins that generate billions of dollars in annual global sales. Incorporated in the US, PROLOR Biotech has offices and research and development facilities in Israel.

Key numbers for fiscal year ending December, 2011:
Sales: $0.0M
Net income: ($15.1)M

Officers:
Chairman: Phillip Frost
CEO and Director: Abraham (Avri) Havron
President and Director: Shai Novik

Competitors:
Amgen
Eli Lilly
Nektar Therapeutics